| OPTIMIzing muScle Preservation in paTients wIth Cirrhosis (NCT05367596) | University of Kansas Medical Center | 2022-06-22 |
| Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) (NCT04210245) | NGM Biopharmaceuticals, Inc | 2020-03-23 |
| Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis (NCT04160897) | Qing XIe | 2019-10-22 |
| Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis (NCT04060147) | Gilead Sciences | 2019-10-17 |
| Microbiome/Peptidome-based Model for Non-invasive Detection of High-risk Gastroesophageal Varices in Compensated Cirrhosis (CHESS1901/APPHA1901) (NCT03990753) | Nanfang Hospital, Southern Medical University | 2019-06-13 |
| Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Hepatitis b Virus Related Compensated Cirrhosis (NCT04196998) | Third Affiliated Hospital, Sun Yat-Sen University | 2019-01-01 |
| An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis (NCT03656068) | Pinnacle Clinical Research, PLLC | 2018-12-04 |
| Detachable String Magnetically Controlled Capsule Endoscopy for Detecting High-risk Varices in Compensated Cirrhosis (NCT03749954) | Nanfang Hospital, Southern Medical University | 2018-11-09 |
| Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV (NCT03037151) | The HIV Netherlands Australia Thailand Research Collaboration | 2018-08-01 |
| Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NCT03439254) | Intercept Pharmaceuticals | 2017-08-30 |
| Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis (NCT02732405) | Istituto Clinico Humanitas | 2016-05-01 |
| A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (NCT02642432) | AbbVie | 2015-12-07 |
| Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease (NCT02207088) | AbbVie | 2014-09-23 |
| A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (NCT02219503) | AbbVie | 2014-09-01 |
| A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV) (NCT01995071) | AbbVie | 2013-11-01 |
| A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis (NCT01704755) | AbbVie (prior sponsor, Abbott) | 2012-10-01 |
| Effects of Weight Loss on Portal Pressure in Patients With Overweight/Obesity and Cirrhosis (NCT01409356) | Hospital Clinic of Barcelona | 2011-10-01 |
| The Natural History and Prognostic Factors of Compensated Cirrhosis. (NCT03144700) | Institute of Liver and Biliary Sciences, India | 2010-01-01 |
| Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis (NCT00190385) | Assistance Publique - Hôpitaux de Paris | 2000-07-01 |